Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.87 |
| ▸ | ARG2 | P78540 | 4/20 | 0.53 |
| ▸ | ARG1 | P05089 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL1000738 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL4583369 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL209698 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL999246 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL209697 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL23295178 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL2182542 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL377041 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL7082500 | 0.98 | GSR (0.83) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL8950821 | 0.94 | GSR (0.77) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182688-A1 | ASSAYS FOR FIXED DOSE COMBINATIONS | F. Hoffmann-La Roche AG (CH) | 2023-05-24 | — | — | EP | claimed |
| CN-115785950-A | Fluorescent probe for expansion-super-resolution microscopic imaging and expansion sample processing method | 浙江大学 | 2023-03-14 | — | — | CN | claimed |
| WO-2022013189-A1 | ASSAYS FOR FIXED DOSE COMBINATIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-01-20 | — | — | WO | claimed |
| EP-3833685-A1 | ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS | Specifica Inc. (US) | 2021-06-16 | — | — | EP | claimed |
| EP-3558920-B1 | IMPROVED SYNTHESIS OF LYSINE ACETYLSALICYLATE · GLYCINE PARTICLES | ASPIAIR GMBH (DE) | 2021-04-07 | — | — | EP | claimed |
| US-20070178219-A1 | Method for Reducing Acrylamide Formation | FRITO-LAY NORTH AMERICA, INC. | 2007-08-02 | — | — | US | claimed |
| US-5547983-A | Aromatic and polycyclic compounds and their use in human or veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-08-20 | — | — | US | claimed |
| EP-4631952-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| CN-118020912-A | High-yield spice extraction process | 湖北周黑鸭食品工业园有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117957258-A | Protease-mediated targeting-specific cytokine delivery using fusion polypeptides | 中外制药株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-4301785-A1 | EPHA2 ANTIBODIES | Atreca, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-116240193-B | Choline kinase mutant and application thereof in production of citicoline | 北京量维生物科技研究院有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-5571892-A | HAVING A C-TERMINUS; TREATMENT FOR AIDS | SEIKAGAKU KOGYO CO., LTD. (JP) | 1996-11-05 | — | — | US | disclosed |
| EP-0502198-B1 | NOVEL POLYPEPTIDE AND ANTI-HIV DRUG PREPARED THEREFROM | SEIKAGAKU KOGYO CO LTD (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5252469-A | Culturing the microorganism in the absence of calcium ion | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| US-4886876-A | Factor VIII coagulant polypeptides | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-12-12 | — | — | US | disclosed |
| US-4657894-A | New factor VIII coagulant polypeptides | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1987-04-14 | — | — | US | disclosed |
| US-4327075-A | IMMUNOLOGY | AB BONNIERFORETAGEN (SE) | 1982-04-27 | — | — | US | disclosed |
| US-3981772-A | Method of attenuating viruses with simultaneous stabilization of their antigens using selected aminomethylol compounds | POVERENNY ALEXANDR MIKHAILOVIC | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | GSR 3481/4885ARG2 3757/4885ARG1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.